Patents Examined by Maria Marvich
  • Artificial antigen presenting cells having a defined and dynamic shape
    Patent number: 10758487
    Abstract: Compositions and methods comprising asymmetrical artificial antigen presenting cells (aAPCs) are disclosed. The non-spherical aAPCs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: September 1, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jordan J. Green, Joel C. Sunshine, Karlo Perica, Jonathan Schneck
  • RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
    Patent number: 10760064
    Abstract: Methods and constructs for RNA-guided targeting of transcriptional activators to specific genomic loci.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 1, 2020
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Morgan Maeder
  • Compositions and methods for enhancing visual function
    Patent number: 10745453
    Abstract: The present disclosure provides a method of restoring or enhancing visual function in an individual, the method comprising administering to the individual a nucleic acid comprising a nucleotide sequence encoding one or more of a medium wavelength cone opsin (MW-opsin), a long wavelength cone opsin (LW-opsin), and a short wavelength cone opsin (SW-opsin). One or more of the MW-opsin, LW-opsin, and SW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 18, 2020
    Assignee: The Regents of the University of California
    Inventors: Ehud Y. Isacoff, Michael H. Berry, Amy Holt, Meike Visel, Autoosa Salari, John G. Flannery, Benjamin M. Gaub
  • Engineered cells for adoptive cell therapy
    Patent number: 10738278
    Abstract: Provided are engineered cells for adoptive therapy, including NK cells and T cells. Also provided are compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some aspects, features of the cells and methods provide specificity and/or efficacy. In some embodiments, the cells contain genetically engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and costimulatory receptors. In some embodiments, the cells include receptors targeting multiple antigens. In some embodiments, the cells include repression of one or more gene product, for example, by disruption of a gene encoding the gene product. In some embodiments, a gene encoding an antigen recognized by the engineered antigen receptor is disrupted, reducing the likelihood of targeting of the engineered cells.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 11, 2020
    Assignee: Juno Therapeutics, Inc.
    Inventors: Kendall M. Mohler, Hyam I. Levitsky
  • Generation of induced pluripotent stem cells from normal human mammary epithelial cells
    Patent number: 10738323
    Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 11, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Xiaojiang Cui, Sareen Dhruv, Loren A. Ornelas
  • Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
    Patent number: 10722598
    Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 28, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
  • Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn
    Patent number: 10717992
    Abstract: The invention provides compositions and methods for regulating thermogenesis and muscle inflammation through modulation of Metrnl and/or Metrn activity and/or expression. Also provided are methods for preventing or treating metabolic disorders and muscle inflammation disorders in a subject through modulation of Metrnl and/or Metrn activity and/or expression. Further provided are methods for identifying compounds that are capable of treating metabolic disorders and muscle inflammation disorders by modulating Metrnl and/or Metrn activity and/or expression.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 21, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Rajesh R. Rao, Jonathan Z. Long
  • Methods and compositions for increased transgene expression
    Patent number: 10717993
    Abstract: Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: July 21, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Gary Ka Leong Lee
  • Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
    Patent number: 10695441
    Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: June 30, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
  • Compositions and methods for treating cancer with DuoCARs
    Patent number: 10689431
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: June 23, 2020
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Genetically-modified cells and method for producing same
    Patent number: 10683355
    Abstract: Production of a chimeric antigen receptor (CAR) expressing cell having excellent target cytotoxicity. Provided is a genetically modified cell comprising, introduced thereinto, a polynucleotide encoding a chimeric antigen receptor (CAR) protein having a target binding domain that specifically binds to a human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, a transmembrane domain and an intracellular signaling domain.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: June 16, 2020
    Assignees: KISSEI PHARMACEUTICAL CO., LTD., SHINSHU UNIVERSITY
    Inventors: Yozo Nakazawa, Kazuyuki Matsuda, Shigeru Nakano
  • Chimeric protein toxins for expression by therapeutic bacteria
    Patent number: 10676723
    Abstract: Bacteria with tumor-targeting capability express, surface displayed, secreted and/or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: June 9, 2020
    Inventors: David Gordon Bermudes, David Quintero
  • Attenuated reovirus
    Patent number: 10668119
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 2, 2020
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • Simian adenovirus and hybrid adenoviral vectors
    Patent number: 10646587
    Abstract: Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 12, 2020
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
  • Method of modulating cell resistance
    Patent number: 10640778
    Abstract: The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: May 5, 2020
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Rodolphe Barrangou, Patrick Boyaval, Christophe Fremaux, Philippe Horvath, Dennis Romero
  • Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
    Patent number: 10610606
    Abstract: Provided herein are adeno-associated virus (AAV) compositions that can express a phenylalanine hydroxylase (PAH) polypeptide in a cell, thereby restoring the PAH gene function. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 7, 2020
    Assignee: HOMOLOGY MEDICINES, INC.
    Inventors: Albert Barnes Seymour, Seemin Seher Ahmed, Jason Boke Wright, Serena Nicole Dollive, Hillard Rubin
  • Inducible production-phase promoters for coordinated heterologous expression in yeast
    Patent number: 10612032
    Abstract: Inducible promoters for the coordinated expression of at least one heterologous gene in yeast and methods of using them are disclosed. In particular, the invention relates to sets of inducible promoters derived from S. cerevisiae and related species that can be induced in the presence of nonfermentable carbon sources.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: April 7, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Colin Harvey, Ulrich Schlecht, Maureen Elizabeth Hillenmeyer
  • Methods and compositions for transducing lymphocytes and regulated expansion thereof
    Patent number: 10596274
    Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.
    Type: Grant
    Filed: March 19, 2017
    Date of Patent: March 24, 2020
    Assignee: Exuma Biotech Corp.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga
  • Genomic insulator elements and uses thereof
    Patent number: 10590433
    Abstract: Provided herein are methods for identifying high potency genomic insulator elements that can be used in a vector composition e.g., that are useful for preventing unwanted expression of neighboring genes, such as proto-oncogenes, when administered to a subject in need thereof. Also provided herein are methods for treating disease and methods for administering a nucleic acid to a subject using such vectors.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: March 17, 2020
    Assignee: University of Washington
    Inventors: George Stamatoyannopoulos, John Stamatoyannopoulos
  • Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
    Patent number: 10584351
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: March 10, 2020
    Assignee: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler